The article details the celestial configuration of the waning Moon and Regulus in the constellation Leo for observation on October 15. Regulus is identified as a magnitude 1.4, quadruple-star system, ...

This is “Looking UP! in southern Colorado,” from the Colorado Springs Astronomical Society. I’m Hal Bidlack, and there are lots of reasons to look up! As you look up in the southern Colorado sky, did ...

Maybe the third time's the charm? Regulus Therapeutics is once again shuffling its pipeline and sliding a new kidney disease candidate into the high-priority queue, hoping for better fortunes after a ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

Novartis has agreed to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen, to bolster its renal disease offerings. The upfront cash payment represents a significant premium over ...

Regulus Therapeutics has axed 30% of its workforce to conserve cash for its stuttering pipeline. And CEO Paul Grint, M.D., is one of those heading to the exit, having decided to hand in his notice and ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Breaking space news, the latest updates on rocket launches, skywatching events and more! You are ...

Forbes contributors publish independent expert analyses and insights. An award-winning reporter writing about stargazing and the night sky. This weekend, a beautiful crescent moon will dominate the ...

Breaking space news, the latest updates on rocket launches, skywatching events and more! You are now subscribed Your newsletter sign-up was successful Want to add more newsletters? Delivered daily ...

Regulus Therapeutics (NASDAQ:RGLS) shares tumbled 24% Wednesday after the biotech company reported results from a study analysis for its ADPKD program and issued a regulatory update. Regulus ...

Novartis AG (NYSE:NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. The upfront cash portion of the ...

We can readily understand why investors are attracted to unprofitable companies. For example, Regulus Resources (CVE:REG) shareholders have done very well over the last year, with the share price ...